Introduction
Methods
Ethics statement
Database
Study population
Prespecified covariates
Propensity score methods
Statistical analysis
Results
Variables | ETCO2 group | Untreated group |
P value | ||
---|---|---|---|---|---|
(n = 83) | (n = 4958) | ||||
Male, no. (%) | 44 | 53.0 | 3138 | 63.3 | 0.054 |
Mean age in years (SD) | 71.3 | 15.2 | 67.9 | 17.6 | 0.088 |
Attempted defibrillation, no. (%) | 14 | 16.9 | 878 | 17.7 | 0.842 |
Mean CPR time (10 min) (SD) | 2.4 | 1.4 | 2.4 | 1.6 | 0.927 |
Socioeconomic status, no. (%) | 0.236 | ||||
Low | 56 | 67.5 | 3586 | 72.3 | |
Moderate | 26 | 31.3 | 1212 | 24.5 | |
High | 1 | 1.2 | 160 | 3.2 | |
Urbanization level, no. (%) | 0.118 | ||||
Urban | 26 | 31.3 | 1174 | 23.7 | |
Suburban | 29 | 35.0 | 2259 | 45.6 | |
Rural | 28 | 33.7 | 1525 | 30.7 | |
Diabetes, no. (%) | 25 | 30.1 | 1255 | 25.3 | 0.318 |
Hypertension, no. (%) | 43 | 51.8 | 2434 | 49.1 | 0.624 |
Coronary artery disease, no. (%) | 16 | 19.3 | 1075 | 21.7 | 0.598 |
Hyperlipidemia, no. (%) | 21 | 25.3 | 893 | 18.0 | 0.087 |
Malignancies, no. (%) | 6 | 7.2 | 231 | 4.7 | 0.273 |
Heart failure, no. (%) | 1 | 1.2 | 255 | 5.1 | 0.105 |
Atrial fibrillation, no. (%) | 3 | 3.6 | 107 | 2.2 | 0.368 |
Charlson comorbidity index score, no. (%) | 0.821 | ||||
0 | 25 | 30.1 | 1631 | 32.9 | |
1 | 24 | 28.9 | 1307 | 26.4 | |
≥ 2 | 34 | 41.0 | 2020 | 40.7 | |
Intracerebral hemorrhage, no. (%) | 1 | 1.2 | 108 | 2.2 | 0.545 |
Ischemic stoke, no. (%) | 16 | 19.3 | 887 | 17.9 | 0.744 |
Chronic renal insufficiency, no. (%) | 2 | 2.4 | 233 | 4.7 | 0.326 |
Liver cirrhosis, no. (%) | 16 | 19.3 | 550 | 11.1 | 0.019 |
Health care institutes, no. (%) | <0.001 | ||||
Medical centers | 36 | 43.4 | 1108 | 22.3 | |
Regional hospitals | 41 | 49.4 | 2497 | 50.4 | |
Local hospitals | 6 | 7.2 | 1333 | 26.9 | |
Clinics | 0 | 0 | 20 | 0.4 | |
Mean propensity score (SD) | 0.046 | 0.041 | 0.016 | 0.021 | <0.001 |
Frequency of ETCO2 use | ||||
---|---|---|---|---|
Year | ETCO2 use | Untreated group | ||
NO. | % | NO. | % | |
2005 | 7 | 1.32 | 522 | 98.68 |
2006 | 2 | 0.35 | 571 | 99.65 |
2007 | 5 | 0.86 | 574 | 99.14 |
2008 | 7 | 1.04 | 666 | 98.96 |
2009 | 0 | 0 | 643 | 100 |
2010 | 7 | 1.07 | 646 | 98.93 |
2011 | 14 | 2.03 | 675 | 97.97 |
2012 | 41 | 5.84 | 661 | 94.16 |
Variables | ETCO2 group | Untreated group |
P value | ||
---|---|---|---|---|---|
(n = 53) | (n = 1060) | ||||
Male, no. (%) | 27 | 50.9 | 644 | 60.8 | 0.154 |
Mean age in years (SD) | 68.9 | 15.9 | 69.6 | 16.7 | 0.776 |
Attempted defibrillation, no. (%) | 11 | 20.8 | 183 | 17.3 | 0.513 |
Mean CPR time (10 min) (SD) | 2.7 | 1.4 | 2.5 | 1.6 | 0.394 |
Socioeconomic status, no. (%) | 0.864 | ||||
Low | 38 | 71.7 | 727 | 68.6 | |
Moderate | 14 | 26.4 | 316 | 29.8 | |
High | 1 | 1.9 | 17 | 1.6 | |
Urbanization level, no. (%) | 0.929 | ||||
Urban | 13 | 24.5 | 276 | 26.0 | |
Suburban | 23 | 43.4 | 469 | 44.3 | |
Rural | 17 | 32.1 | 315 | 29.7 | |
Diabetes, no. (%) | 11 | 20.8 | 272 | 25.7 | 0.424 |
Hypertension, no. (%) | 26 | 49.1 | 521 | 49.2 | 0.989 |
Coronary artery disease, no. (%) | 10 | 18.9 | 200 | 18.9 | 1.000 |
Hyperlipidemia, no. (%) | 10 | 18.9 | 211 | 19.9 | 0.853 |
Malignancies, no. (%) | 3 | 5.7 | 44 | 4.2 | 0.594 |
Heart failure, no. (%) | 1 | 1.9 | 19 | 1.8 | 0.959 |
Atrial fibrillation, no. (%) | 1 | 1.9 | 16 | 1.5 | 0.827 |
Charlson Comorbidity Index score, no. (%) | 0.935 | ||||
0 | 19 | 35.9 | 355 | 33.5 | |
1 | 15 | 28.3 | 305 | 28.8 | |
≥ 2 | 19 | 35.9 | 400 | 37.7 | |
Intracerebral hemorrhage, no. (%) | 1 | 1.9 | 26 | 2.5 | 0.794 |
Ischemic stoke, no. (%) | 8 | 15.1 | 198 | 18.7 | 0.512 |
Chronic renal insufficiency, no. (%) | 2 | 3.8 | 36 | 3.4 | 0.883 |
Liver cirrhosis, no. (%) | 4 | 7.6 | 128 | 12.1 | 0.320 |
Health care institutes, no. (%) | 0.959 | ||||
Medical centers | 15 | 28.3 | 288 | 27.2 | |
Regional hospitals | 32 | 60.4 | 639 | 60.3 | |
Local hospitals | 6 | 11.3 | 133 | 12.6 | |
Clinics | 0.0209 | 0.0125 | 0.0207 | 0.0125 | 0.917 |
ETCO2 group (n) | Untreated group (n) | ORs (95 % CI) | Risk differences (95 % CI) | ||
---|---|---|---|---|---|
Original group | ROSC(+) | 25 | 633 | 2.95 (1.83–4.74) | 0.17 (0.07–0.27) |
ROSC(−) | 58 | 4325 | |||
1:4 matched cohort | ROSC(+) | 25 | 56 | 2.12 (1.23–3.68) | 0.13 (0.02–0.23) |
ROSC(−) | 58 | 276 | |||
1:20 matched cohort | ROSC(+) | 15 | 150 | 2.39 (1.29–4.46) | 0.14 (0.02–0.26) |
ROSC(−) | 38 | 910 |